Finally, in some clinical cases without tissue samples available for histological evaluation, the liquid biopsy may progressively represent a reliable tool for molecular testing, as also confirmed in our recent experience with an NSCLC patient who successfully underwent anti-EGFR-targeted therapy prescribed after a cfDNA screening [51]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.